Trials / Unknown
UnknownNCT05114707
Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses
Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses: a Phase II Multicenter Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Patients with locoregional cancer of nasal cavity and paranasal sinuses are candidate for this study. All the eligible patients receive three cycles of induction chemotherapy (docetaxel 60mg/m2+cisplatin 60mg/m2+5-FU2.5g/m2,civ48h, q3w) followed by concurrent two cycles of cisplatin (80mg/m2,q3w) with curative intensity modulated radiotherapy. Besides, camrelizumab (200mg) is administrated every three weeks for a total of 11 cycles since the first day of induction chemotherapy. We aim to evaluate the three years failure free survival of these patients by the combination of camrelizumab with curative radiotherapy and chemotherapy.
Conditions
- Nasal Cavity Cancer
- Paranasal Sinus Cancer
- Camrelizumab
- Induction Chemotherapy
- Intensity Modulated Radiotherapy
- Concurrent Chemotherapy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | camrelizumab | Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy. |
Timeline
- Start date
- 2021-04-16
- Primary completion
- 2024-04-16
- Completion
- 2024-04-16
- First posted
- 2021-11-10
- Last updated
- 2021-11-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05114707. Inclusion in this directory is not an endorsement.